Latest / Seth Farbman on Podcast - From Startup to Stock Exchange
Overnight' Success's Cost? 25 Years – Propanc Biopharma CEO’s 25 Year Grind | Seth Farbman’s Podcast
What if cancer could be turned from a killer into a manageable chronic illness with no hair loss, no nausea, and no immunosuppression?
In this gripping episode of Startup to Stock Exchange, host Seth Farbman goes deep with James Nathanielsz, CEO of NASDAQ-listed Propanc Biopharma (PPCB).
From a 17-year grind raising over $30M, battling economic crashes, COVID, and regulatory wars, to compassionate-use stories where terminal patients defied odds and lived years longer, James reveals the science behind their novel proenzyme therapy PRP.
Now NASDAQ-uplisted and gearing up for a landmark Phase 1b…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.